What it's for (Indications)
- Olanzapine is an atypical antipsychotic primarily indicated for the treatment of schizophrenia.
- It is effective in managing both positive symptoms (e.
- g.
- , hallucinations, delusions, thought disorders) and negative symptoms (e.
- g.
- , affective flattening, alogia, avolition) associated with this chronic psychiatric disorder.
- Additionally, olanzapine is approved for the acute and maintenance treatment of bipolar I disorder, including manic or mixed episodes and the prevention of recurrence of mood episodes.
- It can be used as monotherapy or in combination with other mood stabilizers like lithium or valproate.
- In some specific cases, it is also indicated for treatment-resistant depression when used in combination with fluoxetine, particularly for depressive episodes associated with bipolar I disorder.
- Its broad spectrum of efficacy across these severe mental health conditions underscores its significant role in psychopharmacology, aiming to stabilize mood and improve thought processes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of olanzapine must be individualized based on patient response and tolerability, always under the supervision of a healthcare professional. For schizophrenia, the usual starting dose is 5 to 10 mg once daily, with a target dose range typically between 10 to 20 mg per day. Dosage adjustments should be made at intervals of not less than 24 hours. For bipolar mania or mixed episodes, monotherapy usually starts at 10 to 15 mg once daily, with the range often up to 20 mg per day. When combined with lithium or valproate, a starting dose of 10 mg once daily is common. For the maintenance treatment of bipolar I disorder, the recommended dose is 5 to 20 mg once daily. Doses should be carefully titrated, and lower starting doses may be necessary for elderly patients, those with hepatic or renal impairment, or individuals predisposed to orthostatic hypotension, to minimize potential adverse effects and ensure patient safety and optimal therapeutic outcomes. |
Safety & Warnings
Common Side Effects
- Olanzapine can cause a range of side effects, some of which require close monitoring.
- Common side effects include somnolence (drowsiness), weight gain, dry mouth, constipation, dizziness, and increased appetite.
- Metabolic side effects are a significant concern, encompassing hyperglycemia (high blood sugar), dyslipidemia (abnormal lipid levels), and an increased risk of type 2 diabetes mellitus, necessitating regular monitoring of blood glucose and lipid profiles.
- Other potential adverse reactions include orthostatic hypotension, which can lead to falls, particularly in elderly patients, and anticholinergic effects.
- Less common but serious side effects include tardive dyskinesia, neuroleptic malignant syndrome (NMS), seizures, and elevations in liver enzymes.
- Patients should be advised to report any unusual symptoms promptly, and clinicians must assess the risk-benefit profile carefully, especially considering long-term use and potential metabolic complications that can impact overall cardiovascular health.
Serious Warnings
- Black Box Warning: Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk compared to placebo-treated patients.
- Olanzapine carries several important warnings and precautions.
- It is not approved for the treatment of dementia-related psychosis, as elderly patients with this condition treated with antipsychotic drugs are at an increased risk of death.
- Patients should be monitored for the development of neuroleptic malignant syndrome (NMS), a potentially fatal syndrome characterized by hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability.
- Tardive dyskinesia, an irreversible syndrome of involuntary movements, can develop, and its risk increases with the duration of treatment and cumulative dose; discontinuation should be considered if signs appear.
- Metabolic changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain, are common and require diligent monitoring throughout treatment.
- Other warnings include orthostatic hypotension, leukopenia/neutropenia/agranulocytosis, seizures, and potential anticholinergic effects.
- Patients with known cardiovascular disease, cerebrovascular disease, or conditions predisposing them to hypotension should be treated with caution.
- Regular clinical and laboratory assessments are crucial to mitigate these risks.
How it Works (Mechanism of Action)
Olanzapine is classified as an atypical (second-generation) antipsychotic, exerting its therapeutic effects through a complex multi-receptor antagonism profile. Its primary mechanism involves potent antagonism of both dopamine D2 and serotonin 5-HT2A receptors. The D2 receptor antagonism is fundamental to its antipsychotic efficacy, particularly in reducing positive symptoms of schizophrenia, by moderating excessive dopaminergic activity in the mesolimbic pathway. Concurrently, its robust antagonism of serotonin 5-HT2A receptors is believed to contribute to its broader efficacy, addressing both positive and negative symptoms of schizophrenia, as well as mood stabilization in bipolar disorder, and potentially mitigating the risk of extrapyramidal symptoms (EPS) often associated with D2 antagonism alone. This is thought to occur by enhancing dopamine release in certain brain regions, offsetting D2 blockade. Furthermore, olanzapine also exhibits significant affinity and antagonistic activity at several other neurotransmitter receptors, including serotonin 5-HT2C, 5-HT3, and 5-HT6 receptors; muscarinic M1-M5 cholinergic receptors; alpha-1 adrenergic receptors; and histamine H1 receptors. The blockade of H1 receptors contributes to its sedative properties and potential for weight gain, while M1 receptor antagonism can lead to anticholinergic side effects such as dry mouth and constipation. Alpha-1 adrenergic blockade can result in orthostatic hypotension. The unique balance of these receptor interactions, particularly the combined D2 and 5-HT2A antagonism, distinguishes olanzapine's pharmacological profile and underpins its clinical utility in various severe mental health conditions.